Founded in 2020, ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), the firm is employing its massively parallel, multiplexed and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/23/21 | $50,000,000 | Series A |
Alexandria Venture Investments Alta Partners  ARCH Venture Partners In-Q-Tel Longwood Fund Pitango HealthTech Redwood Capital Investments Section 32 Tekla Capital Management Xfund | undisclosed |
